TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally, twice daily for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
Study: NCT04329442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine / Tenofovir Disoproxil Oral Tablet
Description: 30 day supply of 200mg tablets
Study: NCT02319915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study: NCT04094623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Description: 15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Social support group therapy
Description: 15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
Study: NCT02045173

Intervention type: OTHER
Group type: OTHER
Intervention: Apneascan TM
Description: Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM

Intervention type: DEVICE
Group type: OTHER
Intervention: Polysomnography/polygraphy
Description: 1 night polysomnography/polygraphy
Study: NCT04710420

Intervention type: DEVICE
Intervention: Endovascular therapy
Description: Endovascular treatment for critical limb threatening Ischemia

Intervention type: DEVICE
Intervention: Endovascular therapy
Description: Endovascular treatment for critical limb threatening Ischemia

Intervention type: DEVICE
Intervention: Endovascular therapy
Description: Endovascular treatment for critical limb threatening Ischemia

Intervention type: DEVICE
Intervention: Endovascular therapy
Description: Endovascular treatment for critical limb threatening Ischemia
Study: NCT05289531

Intervention type: PROCEDURE
Intervention: Rectal Resection Patients
Description: Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery

Intervention type: PROCEDURE
Intervention: Rectal Resection Patients
Description: Patients who have had low anterior resection of rectum was categorized for their quality of life related to surgery
Study: NCT02986971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New IMD
Description: The contraceptive implants of the subjects in this arm are removed by the new IMD.
Study: NCT03114488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial electrical stimulator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial electrical stimulator
Study: NCT00428129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: microplasmin
Description: 20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
Study: NCT01690637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir phosphate suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03877731

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: isolated septal myectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: septal myectomy + edge-to-edge mitral valve repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: septal myectomy + posterior leaflet sliding plasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: septal myectomy + secondary chordae transection
Study: NCT00856648

Intervention type: DEVICE
Intervention: SmartPill ingestion and monitoring
Description: The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.

Intervention type: DEVICE
Intervention: SmartPill ingestion and monitoring
Description: The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
Study: NCT03400644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical collar
Description: Cervical neck collar which is routinely made for post-laminoplasty patients
Study: NCT02098824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: Single administration of capsule containing 16 mg of Galantamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Single administration of capsule containing 10 mg of Methylphenidate
Study: NCT01085617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total-body irradiation
Study: NCT02098824

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration of capsule containing placebo
Study: NCT04547790

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: One level scoop (12.5mL) of 5.1g of psyllium fiber twice a day with 8 ounces water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Dextrin
Description: One level scoop (12.5 mL) of 1.7g wheat dextrin fiber twice a day with 8 ounces water
Study: NCT01646073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: adalimumab eow

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02319915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Study: NCT03034811

Intervention type: DEVICE
Group type: OTHER
Intervention: Persona Partial Knee system
Description: Fixed bearing partial knee
Study: NCT05111808

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Methylene blue fluorescence
Description: IV administration of methylene blue, detection with deep infrared camera and light source
Study: NCT00750880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv (60 minute infusion)
Study: NCT04102670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy
Description: Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
Study: NCT01085617

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study: NCT04102670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeomin
Description: Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero Balance
Description: Horizontal necklace lines will be filled using Beletero Balance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilute Radiesse
Description: The chest area will be injected with dilute Radiesse to stimulate collagen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neocutis Micro Firm Face and Neck Cream
Description: Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
Study: NCT00956956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: 3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally Q6 hours for 7 days of dosing.
Study: NCT02613949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RINCE
Description: The NeuroPoint device is used to deliver repeat applications of RINCE therapy
Study: NCT03432156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Tcm cells immunotherapy
Description: Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
Study: NCT02409810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
Study: NCT03135626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProRoot (Aggregate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTA Plus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Sulfate 20 % Dental Gel
Study: NCT04400942

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasonographic scan aims to evaluate number, size (diameter and volume), location and appearance of submucous uterine myomas, concomitant presence of adenomyosis

Intervention type: BEHAVIORAL
Intervention: Anamnesis
Description: Anamnesis aims to collect data about age, BMI, previous hormonal therapies (such as ulipristal acetate or gonadotropin-releasing hormone agonists) with submucous uterine myomas

Intervention type: PROCEDURE
Intervention: Operative hysteroscopy
Description: Operative hysteroscopy allows a direct evaluation of number, size (diameter and volume), location and appearance of submucous uterine myomas. This exam allows the resection of the myomas.
Study: NCT01460316

Intervention type: BIOLOGICAL
Intervention: Bood sampling for biochemicals and genetic analysis
Description: There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol

Intervention type: BIOLOGICAL
Intervention: Bood sampling for biochemicals and genetic analysis
Description: There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
Study: NCT00917111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal CO2
Description: Four times a day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo Gas
Description: Placebo
Study: NCT02932683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedNav
Description: MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
Study: NCT04889118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for lenvatinib
Description: Oral capsule
Study: NCT00372970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: 200 U given by injection into the pylorus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline injection into pylorus.
Study: NCT00938561

Intervention type: DRUG
Intervention: Inulin
Study: NCT03768544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help guided by a lay provider
Description: Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-help guided by a lay provider
Description: Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting list where participants wait for delayed treatment
Description: Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
Study: NCT03364959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroids inhalation
Description: Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corticosteroids inhalation
Description: Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
Study: NCT03273075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor
Description: The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor
Description: The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
Study: NCT00573248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Patch
Study: NCT03583073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Referral/Linkage to Care
Description: The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Referral to the Coordinated Specialty Care (CSC) clinic
Study: NCT04254809

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy Social Living
Description: To control for potential effects of time and presentation of educational material on study outcome variables, participants randomized to the control intervention will complete a computerized psychoeducation program regarding the benefits of social support networks. Across approximately 20 minutes of audiovisual slides, participants are informed of the ways in which social connections buffer against loneliness and facilitate social learning, provided tips for expanding and maintaining their social network, and administered a brief quiz to assess for comprehension.
Study: NCT01396655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)
Description: The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
Study: NCT01643239

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm
Description: the mCIT group with individualized intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-based mCIT
Description: the mCIT group with individualized intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital-based TR
Description: OT or PT or therapist-based training
Study: NCT03025451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Complete Health Improvement Program
Description: CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (\>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
Study: NCT00890916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FIRSTHAND System
Description: Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
Study: NCT00869115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Istaroxime
Description: Placebo continuous i.v. infusion for 24 hours
Study: NCT01447758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102
Description: Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 29102 Cream Vehicle
Description: Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
Study: NCT04162327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI315
Description: Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI315
Description: Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
Study: NCT00499473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00514150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate plus normal saline 0.9%
Description: IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
Study: NCT04578678

Intervention type: OTHER
Intervention: Steering
Description: Fine tuning of the STN-DBS settings

Intervention type: OTHER
Intervention: Steering
Description: Fine tuning of the STN-DBS settings

Intervention type: OTHER
Intervention: Steering
Description: Fine tuning of the STN-DBS settings
Study: NCT01298973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viscoat
Description: One group will receive Viscoat for incision closure
Study: NCT00514150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline 0.9%
Description: IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
Study: NCT01206439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: nebivolol 5 or 10 mg oral, daily